R&D News
-
-
- 2020-12-28
Annual Review | Top 10 Innovations of Fosun in 2020
The long-lasting 2020 is finally coming to an end. "Don't miss any opportunities from the crisis", Chairman Guo said. The year 2020 has witnessed our resilience in facing the crisis and unleashed our potential in organizational ecology, which makes us more determined to further make in-depth exploration and innovation in the industry. Moreover, this crisis provides us with an opportunity to participate in a scientific and technological breakthrough that would change the history of mankind.
-
-
-
- 2020-11-26
BioNTech and Fosun Pharma Announce the Start of Phase II Clinical Trial of Lead mRNA COVID-19 Vaccine BNT162b2 in China
he phase 2 clinical trial of BNT162b2 vaccine in China will be conducted by Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province).
-
-
-
- 2020-11-13
Fosun Pharma and BioNTech Receive Approval to Commence COVID-19 Vaccine Candidate BNT162b2 Trial in China
Mainz, Germany, and Shanghai, China, November 16, 2020 – Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK) and BioNTech SE (“BioNTech”; Nasdaq: BNTX,) today announced that the China National Medical Products Administration (hereinafter referred to as the "National Medical Products Administration") has approved the clinical trial in Mainland China for their mRNA vaccine candidate, BNT162b2.
-
-
-
- 2020-11-13
IND Application of Henlius Daratumumab Biosesimilar Accepted by NMPA
Multiple Myeloma is the second most common cancer among all types of hematologic malignancies and accounts for approximately 10% of hematologic malignant cases. Multiple myeloma is characterized by proliferative disorder of bone marrow plasma cells that can lead to bone marrow damage.
-
-
-
- 2020-11-11
First Group of Subjects Dosed with Innovator Drug for Gout FCN-207 Tablets of Fochon Pharmaceuticals, Ltd.
On November 11, 2020, the first group of subjects in the Phase I clinical study of a selective URAT1 inhibitor, FCN-207 Tablets, independently developed by Chongqing Fochon Pharmaceuticals Ltd. (hereinafter referred to as "Fochon Pharmaceuticals") was administered in Peking University Third Hospital.
-
-
-
- 2020-11-06
Second Drug Candidates for the Treatment of COVID-19! Henlius ACE2-Fc Fusion Protein HLX71 Receives IND Approval from US FDA
HLX71 is a recombinant human angiotensin converting enzyme 2 (hACE2) fusion protein with IgG1 Fc at the C-terminal, which is independently discovered and developed by Henlius. Binding of the RBD domain on the S1 subunit of the viral spike protein with hACE2 will lead to cell endocytosis of the virus
-
-
-
- 2020-10-29
Fochon Pharmaceuticals, Ltd. (Subsidiary of Fosun Pharma) Announces Licensing Agreement with Eli Lilly for Novel Selective BCL-2 Inhibitor
“Fochon is committed to developing innovative therapeutics to improve people’s health and lives. FCN-338 has the potential to become an improved option for cancer patients as a potent and selective inhibitor of BCL-2, a key target in anti-apoptotic pathways,”
-
-
-
- 2020-10-10
First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency evalsuation
Recently, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), a member enterprise of Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma"), received the Notice on Approval of Supplementary Drug Application for Perphenazine Tablets (2 mg, 4 mg) (No.: 2020B04654, 2020B04655) from NMPA. The drug is the first of its kind in China to pass the consistency evalsuation of quality and efficacy of generic drugs.
-
-
-
- 2020-10-09
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
HLX70 is a genetically engineered fully humanized monoclonal antibody that targets the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 spike protein (S protein) and is a typical IgG1 Kappa immunoglobulin.
-